Kendle will acquire the Phase II-IV Clinical Services business of Charles River Laboratories International, Inc. for approximately $215 million in cash. The move will strengthen Kendle’s position in the clinical development industry, adding therapeutic expertise, diversifying its customer base and expanding its capacity for global trials. The transaction is expected to close in the third quarter of 2006. The acquired operations will operate under the Kendle name. “We are excited...